Overview
A potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.
Indication
For use in the treatment of subacute or chronic angle-closure glaucoma after iridectomy or where surgery is refused or contraindicated.
Associated Conditions
- Accommodative component in esotropia
- Chronic Angle Closure Glaucoma
- Open Angle Glaucoma (OAG)
- Nonuveitic secondary glaucoma
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2015/09/09 | Phase 4 | Withdrawn | Danbury Eye Physicians & Surgeons, PC |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| PHOSPHOLINE IODIDE - PWS 6.25MG/5ML | storz, division of wyeth-ayerst canada inc. | 02217120 | Powder For Solution - Ophthalmic | 6.25 MG / 5 ML | 4/29/1997 |
| PHOSPHOLINE IODIDE 3MG/5ML | wyeth-ayerst canada inc. | 02238075 | Powder For Solution - Ophthalmic | 3 MG / 5 ML | 12/2/1998 |
| PHOSPHOLINE IODIDE 6.25MG/5ML | wyeth-ayerst canada inc. | 02238076 | Powder For Solution - Ophthalmic | 6.25 MG / 5 ML | 10/6/1999 |
| PHOSPHOLINE IODIDE - PWS 12.5MG/5ML | storz, division of wyeth-ayerst canada inc. | 02217139 | Powder For Solution - Ophthalmic | 12.5 MG / 5 ML | 8/29/1997 |
| PHOSPHOLINE IODIDE - LIQ PWS 3MG/5ML | storz, division of wyeth-ayerst canada inc. | 02217112 | Liquid
,
Powder For Solution - Ophthalmic | 3 MG / 5 ML | 4/29/1997 |
| PHOSPHOLINE IODIDE PWS 6.25MG/5ML | wyeth-ayerst canada inc. | 02043335 | Powder For Solution - Ophthalmic | 6.25 MG / 5 ML | 12/31/1994 |
| PHOSPHOLINE IODIDE 12.5MG/5ML | wyeth-ayerst canada inc. | 02043343 | Powder For Solution - Ophthalmic | 12.5 MG / 5 ML | 12/31/1994 |
| PHOSPHOLINE IODIDE PWS 3MG/5ML | wyeth-ayerst canada inc. | 02043327 | Liquid
,
Powder For Solution - Ophthalmic | 3 MG / 5 ML | 12/31/1994 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.